Opko Health

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Returning buyers and chief executives were among the insiders making purchases this week. Biotechs, REITs and a car rental leader saw notable insider purchasing of shares. Conventional...

Insider buying can be an encouraging signal for potential investors when markets face uncertainty. Insiders at some consumer products companies were adding to their stakes this past week. A few biotech companies saw insiders acquiring some shares as well. Conventional wisdom says that insiders...

Insider buying can be an encouraging signal for potential investors. A couple of Singapore-based beneficial owners made notable insider buys this past week. Some insiders made return trips to the buy window as well. Conventional wisdom says that insiders and 10-percent owners really only...

Benzinga has featured looks at many investor favorite stocks over the past week. Bullish calls included a leading semiconductor maker and oilfield services giants. Bearish calls featured a wearable device maker and the world's largest retailer. Volatility was turned up again last...

Insider buying can be an encouraging signal for potential investors. Several health care companies saw notable insider buying this past week. Insiders included a company founder and a renowned former CEO. Conventional wisdom says that insiders and 10-percent owners really only buy shares...

Insider buying can be an encouraging signal for potential investors. Insiders at three companies made notable share purchases last week. And two of the insiders featured here are regular acquirers of shares. Conventional wisdom says that insiders and 10-percent owners only buy shares of...

Shares of Opko Health Inc. (NASDAQ: OPK), a pharmaceutical and diagnostics company, plunged more than 15 percent on Friday after the company reported disappointing results to a clinical trial. In a press release, Opko Health announced data analysis from a Phase 3 trial which evaluated its long-...

Insider buying has dwindled as the markets have hit new highs and a new earnings season has begun. However, three CEOs seem to have missed the memo and have made notable insider purchases regardless. Strong insider buying is often considered a positive sign for investors, particularly...

Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out among the few that bucked the trend in those two weeks. Shares of both of these stocks rose sharply during the two-week period. Short sellers shied away from many of the...

Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out among the few that bucked the trend in those two weeks. Shares of one of those two stocks slumped more than 22 percent during the period. Short sellers shied away from many of...

Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out as leaders of that trend in those two weeks. Shares of one of those two stocks rose while the other slumped during the period. Short sellers moved on only a few of the leading...

Short interest in many leading biotech stocks declined in the most recent period. Bucking that trend is a biotech company that soon will be acquired by an overseas peer. Short sellers retreated most sharply from a biotech that some analysts now see as a value stock. Between the March 31 and April...